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Abstract. Intracranial hemangiopericytomas (HPCs) are 
rare tumors and their radiological appearance resembles that 
of meningiomas, especially meningothelial meningiomas. To 
increase the knowledge on the biochemical composition of this 
type of tumor for better diagnosis and prognosis, we performed 
a molecular study using ex vivo high resolution magic angle 
spinning (HR-MAS) magnetic resonance spectroscopy 
(MRS) perfomed on HPC and peritumoral edematous tissues. 
Moreover, to help in the discrimination between HPC and 
meningothelial meningioma we compared the ex vivo HR-MAS 
spectra of samples from one patient with HPC and 5 patients 
affected by meningothelial meningioma. Magnetic resonance 
imaging (MRI), in vivo localized single voxel 1H-MRS was 
also performed on the same patients prior to surgery and the 
in vivo and ex vivo MRS spectra were compared. We observed 
the presence of OH-butyrate, together with glucose in HPC 
and a low amount of N-acetylaspartate in the edema, that may 
reflect neuronal alteration responsible for associated epilepsy. 
Many differences between HPC and meningothelial menin-
gioma were identified. The relative ratios of myo-inositol, 
glucose and gluthatione with respect to glutamate are higher 
in HPC compared to meningioma; whereas the relative ratios 
of creatine, glutamine, alanine, glycine and choline-containing 
compounds with respect to glutamate are lower in HPC 
compared to meningioma. These data will be useful to improve 
the interpretation of in vivo MRS spectra resulting in a more 
accurate diagnosis of these rare tumors.
Introduction
Hemangiopericytomas (HPCs) are rare, highly cellular and 
vascular tumors derived from pericytes of Zimmerman, 
which are contractile smooth-muscle cells surrounding the 
endothelium of the capillaries, and are ubiquitous in all types 
of mesenchymal tissue. HPCs may arise in the soft tissues 
anywhere in the body (1,2) and the most common sites are 
head and neck, lower extremities and retroperitoneum. HPCs 
affecting the central nervous system are considered malignant 
(3,4), existing in low-grade and high-grade form with predict-
ably aggressive clinical behavior, including high rates of 
recurrence and distant metastases (5). Macroscopically, HPC 
is a solid tumor that is well demarcated from the adjacent brain 
tissue (3,6). The tumor is typically treated by complete micro-
surgical removal, followed by local irradiation of the tumor 
bed. The majority of tumors can be removed in a seemingly 
complete manner. However, local recurrences are almost ine- 
vitable in the long run and tumor metastasis eventually occurs 
in over 60% of patients after 15 years (3,6,7). Intracranial 
HPCs, classified under the heading of non-meningothelial 
mesenchymal tumors (8), are difficult to distinguish from 
meningiomas based on location, clinical presentation (9-11) 
and brain imaging (5,12-14). Due to their more aggressive 
behavior, intracranial HPCs require different management 
and a correct diagnosis is critical (15-17). However, data from 
two studies (18,19) suggest that the discrimination between 
HPC and meningiomas seems to be possible by using in vivo 
MR spectroscopy (MRS) and the authors hypothesized 
that the discrimination can be obtained based on the much 
higher levels of myo-inositol (Myo) in the HPCs. Moderately 
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increased concentrations of Myo in the in vivo MR spectra of 
four HPCs have been also reported by Fountas et al (10).
Additional studies have reported on the in vivo 1H-MRS 
spectra from HPC, but they are not as informative as high 
resolution magic angle spinning (HR-MAS) MRS about the 
complete metabolic profile of this type of tumor. The choline 
containing compounds (ChoCC) peak is dominant in these 
in vivo spectra (20,21).
HPCs are rare tumors, therefore performing a significant 
study on a large amount of samples in order to improve the 
diagnosis remains a challenge, however it is important to 
know more about the biochemical composition of this tumor. 
With this aim, we studied the metabolic profile of HPC using 
ex vivo HR-MAS MRS, which allows the whole analysis of 
intact tissue with minimal sample preparation (22-24). A 
comparison between the in vivo and ex vivo MRS spectra 
was performed with the goal to better understand HPC and 
edema tissues. Moreover, the difference between the HPC and 
meningothelial meningioma will be highlighted.
Materials and methods
Sample. Informed consent before spectroscopic examination 
was obtained from the patient. MRI and in vivo localized 
single voxel 1H-MRS were performed with a 3 Tesla whole-
body scanner (General Electric Medical Systems, Milwaukee, 
WI) following the routine standard clinical protocol previously 
described (25). MR imaging was performed with T2-weighted 
fast spin-echo (FSE) sequences (TR, 4200 ms; TE, 93 ms; 
NEX, 2; 24-cm field of view; 512x512 matrix; 4-mm sections), 
fluid-attenuated inversion recovery (FLAIR) sequences (TR, 
9002 ms; TE, 91 ms; NEX, 2; 24-cm field of view; 320x320 
matrix; 4-mm sections) in the axial plane, and T1-weighted 
spin-echo (SE) sequences (TR, 560 ms; TE, 18 ms; NEX, 2; 
24-cm field of view; 384x224 matrix; 4-mm sections) in the 
sagittal and coronal planes before administration of a contrast 
agent and coronal and axial planes after administration of a 
contrast agent. For choosing a voxel for spectroscopy, homo-
geneous regions on the T2-weighted image were selected 
carefully excluding cystic, necrotic, or hemorrhagic region.
The volume of interest (VOI) size ranged from 1.2 to 8 cm3. 
1H-MR spectra were acquired before administration of the 
contrast agent with a point-resolved spectroscopy sequence 
(PRESS) for localization, with TR 2000 ms and TE 35 ms, 128 
acquisitions, and a 3-pulse chemical shift selection suppres-
sion (CHESS) sequence to provide water suppression. We used 
automated optimization of gradient shimming, transmitter 
pulse power, and water suppression.
MRI revealed a left frontobasal perisellar lesion. The 
lesion is an extra-axial round mass with homogeneous intense 
enhancement after contrast administration and it is associated 
with severe cerebral edema in underlying brain parenchyma 
and midline shifts. According to Chernov et al (26) the exten-
sion of perilesional edema, evaluated by T2-weighted MR 
image, was graded as severe. The patient received mannitol 
as the only anti-edema drug. After MRI and in vivo MRS 
the patient underwent surgery and one sample was obtained 
from the lesion and a second sample was obtained from the 
edema area. A small portion of tumor and edema, were used 
for HR-MAS MRS analysis. A portion of tumoral specimen 
was used for routine histopathology and revealed a grade II 
WHO HPC (27). During surgery, resected tissue was sent for 
histological analysis, and remainder of the tissue was immedi-
ately frozen in liquid nitrogen and stored at -80˚C until MRS 
analyses. The manipulation time for sample storing under 
nitrogen is around 1 min.
Ex vivo HR-MAS MRS. Before MRS examination, each sample 
was flushed with D2O to improve the homogeneity, the water 
suppression, and to add deuterium as a nucleus for the lock 
system. The sample was introduced in a MAS zirconia rotor 
(4 mm OD) maintained on ice, fitted with a 50-µl cylindrical 
insert to increase sample homogeneity, and then transferred 
into the probe cooled to 4˚C. Total time for sample preparation 
prior to NMR analysis was only a few minutes.
1H and 13C HR-MAS spectra were recorded with a Bruker 
Avance 400 (Bruker BioSpin, Karlsruhe, Germany) spectro-
meter operating at a frequency of 400.13 and 100.61 MHz, 
respectively. The instrument was equipped with a 1H,13C 
HR-MAS probe. Experiments were performed at a tempera-
ture of 4˚C controlled by a Bruker cooling unit.
Samples were spun at 4000 Hz and three different types 
of one-dimensional (1D) proton spectra were acquired by 
using the sequences implemented in the Bruker software: i) 
a composite pulse sequence (zgcppr) (28) with 1.5 s water 
presaturation during the relaxation delay, 8 kHz spectral width, 
32k data points, 32 scans, ii) a water-suppressed spinecho 
Carr-Purcell-Meiboom-Gill (CPMG) sequence (cpmgpr) (29) 
with 1.5 s water presaturation during the relaxation delay, 
1 ms echo time (τ) and 360 ms total spin-spin relaxation delay 
(2nτ), 8 kHz spectral width, 32k data points, 256 scans and iii) 
a sequence for diffusion measurements based on stimulated 
echo and bipolar-gradient pulses (ledbpgp2s1d) (30) with 
∆ 200 ms, eddy current delay Te 5 ms, δ 2x2 ms, sine-shaped 
gradient with 32 G/cm followed by a 200-µs delay for gradient 
recovery, 8 kHz spectral width, 8k data points, 256 scans. 
Two-dimensional (2D) 1H,1H-correlation spectroscopy 
(COSY) (31,32) spectra were acquired using a standard pulse 
sequence (cosygpprqf) and 0.5 s water presaturation during 
relaxation delay, 8 kHz spectral width, 4k data points, 32 scans 
per increment, 256 increments. 2D 1H,1H-total correlation 
spectroscopy (TOCSY) (33,34) spectra were acquired using a 
standard pulse sequence (mlevphpr) and 1 s water presatura-
tion during relaxation delay, 100 ms mixing time (spin-lock), 
4 kHz spectral width, 4k data points, 32 scans per increment, 
128 increments. 2D 1H,13C-heteronuclear single quantum 
coherence (HSQC) (35) spectra were acquired using an echo-
anti-echo phase-sensitive standard pulse sequence (hsqcetgp) 
and 0.5 s relaxation delay, 1.725 ms evolution time, 4 kHz 
spectral width in f2, 4k data points, 128 scans per increment, 
17 kHz spectral width in f1, 256 increments.
Relative quantification of metabolites. In each spectrum, rela-
tive ratios of all of the quantificable metabolites were calculated 
by measuring the area of individual metabolites signal with 
respect to the area of Glu signal at 2.34 ppm. The intensity of 
the Glu remained consistent in HPC and meningioma spectra 
as noted by the visual inspection of the 1H spectra of all tissue 
samples. Metabolite ratios relative to Glu are expressed as 
mean ± SD (standard deviation).
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Results
Typical axial T2-weighted MR images of HPC, edema, axial 
T1-weighted and coronal T1-weighted MR images after 
contrast administration are shown in Fig. 1. The HPC demon-
strate a large abnormal mass with severe edema. T1- and 
T2-weighted MR imaging characteristics, and contrast uptake 
appear compatible with both meningiomas and HPCs. The 
tumor demonstrates heterogeneous intensity being both hypo- 
and isointense to white matter and iso- and hyperintense to 
gray matter. Small vascular elements are evident in the lesion 
(Fig. 1A). Significant edema in underlying brain parenchyma 
is present (Fig. 1B). The lesion shows intense contrast enhance-
ment (Fig. 1C) and dural attachment (Fig. 1D). MRI shows a 
sharply demarcated extra-assial tumor with dural attachment 
in left para/suprasellar region and contrast enhancement on 
T1-weighted images after gadolinium. The lesion is isointense 
with grey matter on T2-weighted images with small hypoin-
tense areas due to vessels. Significant edema in underlying 
brain parenchyma is present.
Fig. 2 shows the ex vivo 1D 1H HR-MAS MR spectra of 
HPC lesion. The spectrum (Fig. 2A) was obtained using a 
conventional 1H spectrum with water presaturation, and it 
represents the global biochemical composition of lesion. The 
second spectrum (Fig. 2B), acquired with a spin-echo sequence, 
displays signals deriving from small metabolites. After the 
analysis several metabolites are identified: 1,2-propanediol 
(1,2-propanendiol is an exogenous compound used as solvent 
in pharmaceutical preparations containing some water-soluble 
ingredients), β-hydroxybutyrate (OH-But), lactate (Lac), alanine 
Figure 1. Axial T2-weighted MR images of HPC (A) and edema (B). Axial 
T1-weighted (C) and coronal T1-weighted (D) after contrast administration.
Figure 2. Ex vivo HR-MAS spectra of HPC lesion: (A) conventional 1H 
spectrum with water presaturation; (B) 1H CPMG spectrum; (C) 1H diffusion 
edited spectrum.
Figure 3. Ex vivo HR-MAS spectra of edema tissues around lesion: (A) con-
ventional 1H spectrum with water presaturation; (B) 1H CPMG spectrum; (C) 
1H diffusion edited spectrum.
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(Ala), acetate (Ac), glutamine plus glutamate (Glx), glutamate 
(Glu), glutamine (Gln), glutathione (GSH), creatine (Cr), 
ChoCC, taurine (Tau), mannitol (Man), Myo, α- and β-glucose 
(α- and β-Glc). The assignment of 1,2-propanediol is based on 
the analysis of 1D 1H, and selected 2D (COSY, TOCSY and 
HSQC) NMR spectra, where we highlight the H-H correla-
tions of 1,2-propanediol. The signals are at 1.14 ppm (d) CH3, 
3.55/3.44 ppm CH2 and 3.87 ppm CH. The spectrum (Fig. 2C) 
was acquired with a diffusion edited sequence and shows the 
contribution from lipids and macromolecules. The complete 
metabolic assignments were confirmed using two dimensional 
COSY, TOCSY and HSQC spectra. All of the experiments 
permit clarification of the metabolite pattern of the lesion and 
the same experiments were also used to characterize the meta-
bolic profile of edema (Fig. 3).
The results were compared with data from the literature 
(36) and, when possible, with the experimental spectra in the 
Human Metabolome Database (37) to assign the different 
metabolites.
The same small metabolites were found in both tumor and 
edema, but in different amounts. For instance, the amount of 
Cr and Myo is lower in the lesion compared to in the edema, 
whereas levels of α- and β-Glc together with Tau seem to be 
higher in the lesion. Furthermore, we observed a different Glu/
Gln ratio in the two types of tissues, and that OH-But and GSH 
were present only in HPC. Different profiles were observed for 
macromolecules (MM) and lipids: HPC diffusion spectrum 
(Fig. 2C) is characterized by the presence of lipids (manly 
triglycerides, probably as lipid bodies) and MM signals, whereas 
that of the edema (Fig. 3C) shows signals mainly due to MM.
Figure 4. 1, The in vivo MRS (A) and ex vivo HR-MAS after line broadening (LB, 10) (B) spectra from HPC. 2, The in vivo MRS (A) and ex vivo HR-MAS 
after line broadening (LB, 5) (B) spectra from the edema.
Figure 5. 1, Ex vivo HR-MAS 1H CPMG spectra: comparison between meningioma (A) and HPC (B). 2, Ex vivo HR-MAS diffusion edited spectra: comparison 
between HPC (A) and meningioma (B).
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A direct comparison between in vivo (TE, 35) and conven-
tional ex vivo spectra of the lesion after a suitable broadening 
process (Fig. 4, panel 1) shows that there is good agreement 
between the two profiles. The main difference between 
in vivo and ex vivo spectra is found in the Man signals due 
to the different magnetic fields used. At 3T, the field for 
in vivo MRS, the signals due to Man appear as a broad signal 
centred at 3.8 ppm, whereas at 9.4T, the field for ex vivo MRS 
spectra, Man signals are distributed in a region between 3.6 
and 4.0 ppm and structured at low line broadening. Man is an 
exogenous metabolite used to reduce brain pressure produced 
by the tumoral mass in patients.
The ex vivo  HR-MAS spectrum of the edema 
(Fig. 4, panel 2B) shows more Lac and MM and less 
N-acetylacetylaspartate (NAA) than the in vivo spectrum 
(Fig. 4, panel 2A). The Lac signal is higher in the ex vivo than 
in the in vivo spectrum of the edema, but this is likely not 
significant, since the Lac signal is always observed in ex vivo 
spectra due to the unavoidable period of ischemia during the 
biopsy procedure (38). The signal usually assigned to NAA 
in the in vivo spectrum at 2.01 ppm in this case receives the 
contributions of Glu and Gln as can be seen from the HR-MAS 
ex vivo spectrum. The decrease in NAA and the increase in 
acetate (Ac) in the 1H ex vivo HR-MAS spectrum of the edema 
are notable (Fig. 3B), suggesting the degradation of NAA to 
Ac and aspartate (39).
Comparing the HR-MAS spectra of HPC and meningioma 
(Fig. 5), we observe many differences between the two tumors. 
The phosphocholine (PC)/choline (Cho) ratio appears to be 
different comparing meningioma to HPC (Fig. 5, panel 1), but 
in our opinion this aspect needs further investigation. In fact, 
we observed a high variability of PC/Cho in our meningioma 
set. It is to be noted that HR-MAS MRS allows the detection of 
Ala in HPC, which has been reported to be absent (19,20). This 
is probably due to the higher sensitivity of HR-MAS MRS with 
respect to in vivo MRS. Nevertheless, both techniques show 
that the Ala content is lower in HPC than in meningioma. The 
diffusion edited spectra of HPC and meningioma are shown in 
Fig. 5, panel 2. The comparison shows a very similar profile 
with slightly higher amounts of lipids in HPC compared to 
meningioma.
Discussion
We applied ex vivo HR-MAS MRS to assess the metabolic 
status of HPC and edema. Several differences in the metabolic 
profile of HPC and edema can be detected.
The resonance deriving from the OH-But was identified in 
the lesion spectrum (Fig. 2B). It has been shown that elevated 
ketone bodies can target brain tumors while enhancing the 
metabolic efficiency of normal neurons glia. Moreover, the 
ketones bodies are toxic to some tumor cells and they might 
restrict availability of glutamine (40-42). In our case, the pre- 
sence of OH-But together with Glc in the lesion could suggest 
the bioenergetic transition from normal to neoplastic brain. In 
contrast to a normal brain, which oxidizes Glc as well as ketone 
bodies for energy, malignant brain tumors are largely depen-
dent on Glc for energy. OH-But is also reported to prolong 
cell survival time and to inhibit cerebral edema by improving 
energy metabolism in the hypoxia, anoxia and global cerebral 
ischemia models. The cerebroprotective effect of OH-But was 
examined in rats with permanent (p)-occlusion and transient 
(t)-occlusion of middle cerebral artery (MCA) (43).
The low intensity of the NAA signal (singlet at 2.01 ppm; 
Fig. 3B) is evident in peritumoral edema tissue analyzed in 
ex vivo, in agreement with the decrease of NAA in peritumoral 
lesion reported in in vivo spectra MRS (25,44). The NAA 
is belived to be a marker of neuronal integrity (45), and its 
decrease in the edema may reflect neuronal alteration respon-
sible for associated epilepsy. Our HR-MAS data obtained 
from biopsy samples confirm a strong neuronal alteration and 
the patient showed neurological disorders, including seizure 
epilepsy. Regional brain reduction of NAA levels measured 
by MRS is a well recognized marker of neuronal or axonal 
loss in many neurologic disorders, including traumatic brain 
injury, ischemic stroke, epilepsy, multiple sclerosis, neoplastic 
and non-neoplastic lesions (46,47).
Another important difference between HPC and edema is 
the Cr amount, which was very low in HPC and higher in the 
edema. This is in agreement with our previous in vivo MRS 
study of peritumoral brain edema where an energy-linked 
metabolic alteration was associated with injury to the myelin 
sheath (25).
The biochemical profile of HPC can be compared with that 
of meningioma, the molecular characterization of which, by 
ex vivo HR-MAS MRS, has already been reported (48,49). The 
more suitable comparison is between HPC and meningothelial 
meningioma, which is the most common meningioma. We 
used the Glu signal at 2.34 ppm as a reference for the analysis 
because this signal does not overlap with others and it is easy 
to integrate. Moreover, we did not observe appreciable differ-
ences among the meningothelial meningioma (grade I) and 
HPC samples.
We observed that the relative ratios of Myo, Glc and GSH 
with respect to Glu are higher in HPC compared to menin-
gioma; and vice versa the relative ratios of Cr, Gln, Ala, Gly 
and ChoCC with respect to Glu are lower in HPC compared to 
meningioma (Table I).
Hypotaurine (HTau) is detected only in meningioma, 
whereas OH-But is present only in HPC. Overall, these data 
Table I. Relative ratios metabolite/Glu from CPMG HR-MAS 
experiments in HPC and MN (meningothelial meningioma).
 HPC MN
Metabolites (1 sample) (5 samples)
Ala 0.3 1.01±0.42
Gln 0.4 0.77±0.34
Cr 0.3 0.59±0.38
ChoCC 1.84 3.39±1.51
Gly 0.14 0.93±0.31
Myo 0.15 0.09±0.08
Glc 0.47 -
GSH 0.24 -
MN values are expressed as mean ± SD (standard deviation).
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are consistent with published studies (19-21). It is difficult to 
quantify the Tau content in HPC due to overlapping signal 
from α-, β-Glc.
In conclusion, HR-MAS spectra permit the characterization 
of the metabolic profiles of HPC and peritumoral edema tissue. 
The presence of OH-But together with Glc in the lesion could 
suggest the bioenergetic transition from normal to neoplastic 
brain. The variations in the NAA amount in the edema area 
may reflect neuronal alteration responsible for associated 
epilepsy. Our HR-MAS data performed on biopsy confirmed a 
strong neuronal alteration, and the patient showed neurological 
disorders including seizure epilepsy.
We identified many differences between HPC and menin-
gioma. The relative ratios of Myo, Glc, and GSH with respect 
to Glu are higher in HPC compared to meningioma; and, vice 
versa, the relative ratios of Cr, Gln, Ala, Gly and ChoCC with 
respect to Glu are lower in HPC compared to meningioma. 
Ala was detected by HR-MAS MRS in HPC but not in vivo 
MRS.
The ex vivo HR-MAS allows for a comprehensive 
metabolic characterization of HPC tissues. We hope that 
identification of key metabolites would provide a basis for 
studies aimed at better understanding of the biochemical 
processes of this tumor. These data obtained from a large 
number of samples would be useful to improve the interpre-
tation of in vivo MRS spectra and allow for better diagnosis 
and prognosis.
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